Q1 2012 venture financing round-up: ortho bucks investment trend and overtakes heart firms
This article was originally published in Clinica
Executive Summary
The arid, post-credit crunch IPO market may be on its way to becoming a hazy memory as the flow of successful medtech floats look to be strengthening as we move well into the first half of 2012. Already, there has been the €38m ($49.6m) flotation of orthopaedics imaging specialist EOS Imaging on the EuroNext (www.clinica.co.uk, 17 February 2012), while Osprey Medical raised Aus$20 ($21m) in its IPO on the Australian Stock Exchange (www.clinica.co.uk, 19 April 2012). There are even more ambitious flotations in the pipeline, such as spinal implant firm Globus's plans to raise $100m in an IPO on the NYSE (www.clinica.co.uk, 2 April 2012) while just this week (7 May), cancer diagnostics firm Cancer Genetics announced it was looking to bag around $48m from its planned IPO on the Nasdaq.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.